Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Brazil / NCT05784038
Recruiting Observational

Observational, Prospective, Cohort Study of Mpox Infection in Brazil (NETPOX)

NCT05784038 · tracked via the Priya Life Science Brazil tracker
Sponsor
Hospital Israelita Albert Einstein
Phase
Observational
Started
2024-07-16
Last updated
2024-07-17

Condition(s) studied

MonkeypoxMPOX

Investigational drug(s) / intervention(s)

Viral genomicUntargeted Metabolomics

Viral genomic: Evaluation of mpox viral genomic

Untargeted Metabolomics: Evaluation of metabolomics of the total plasma, oropharynx, and skin samples.

Study summary

The study is a prospective cohort that evaluates the clinical and immune-metabolic variables that may be linked to the risk and severity of the infection or even hospitalization or death in patients infected with the Mpox virus in Brazil. The expectation is to include at least 80 patients over six months, with a follow-up of 90 days from inclusion, through contact via decentralized visits.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Men and women aged ≥ 18 years with confirmed MPOX infection. (laboratory-confirmed monkeypox infection is defined as determined by PCR, culture, or antigen test obtained from a sample collected from blood, oropharynx, anal or skin lesion within 4 days of randomization) Exclusion Criteria: * Inability to provide informed consent; * Patient who, judging by the study team, does not have a condition for decentralized follow-up

Primary outcome measure(s)

Trial sites (3)

FacilityCityRegionStatus
Hospital Universitário João de Barros Barreto Belém Pará Recruiting
Hospital Israelita Albert Einstein São Paulo São Paulo Recruiting
Hospital Naval Marcílio Dias Rio de Janeiro Brazil Recruiting

More Hospital Israelita Albert Einstein trials in Brazil

Evaluation of the Efficacy of Diagnostic Support Algorithms in Chest X-rays- LuAna Trial Recruiting
Acute Treatment and Long-term Assessment of Adult Infectious Meningitis Recruiting
Gastric Content in Fasting Volunteers and in Tirzepatide Users: an Observational and Cross-sectional Study Recruiting
"Immunoregulation in Atherosclerosis: A Single-Cell RNA Sequencing Study" Starting soon
Study on the Functional Impact of Cosmetics on Improving Self-Esteem and Quality of Life in Black Women Recruiting

Other trials for the same condition

Assessment of the Efficacy and Safety of Tecovirimat in Patients With Monkeypox Virus Disease Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05784038 on ClinicalTrials.gov ↗ ← All trials in Brazil